Christopher Lieu, MD, highlighted the challenge with two-arm trial designs in assessing the contribution of each treatment phase in perioperative settings. The FDA's ODAC stressed that future trials for perioperative therapies in NSCLC should better evaluate each treatment phase's impact. Lieu argued that delaying approval for new therapies due to trial design issues might prevent patients from accessing effective treatments.